ClinicalTrials.gg
Not yet recruitingNCT07874880Updated Oct 15, 2026

MTX-531-001 Phase 1 Study in Advanced Solid Tumors

A Phase 1 interventional study of MTX-531 in Solid Tumors (Phase 1), HNSCC and Endometrial Cancer, sponsored by MEKanistic Therapeutics, Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by MEKanistic Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Updated Oct 15, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 217 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Planned enrollment
329th of 993
71 · median 41
Started
2026
with 59 others
Phase 1
362 of 1,099
71 open now
Primary completion
2028-12
later than 266 of 346 live
Registered
1,094th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 329th largest by planned enrollment of the 993 interventional ones that give a count, is one of 60 that started in 2026, is one of 362 in phase 1, reaches primary completion later than 266 of the 346 other live ones, and was the 1,094th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

217 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

212 more — sign in →

All 217 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

This is a first-in-human, Phase 1, open-label study evaluating MTX-531, an investigational dual EGFR/PI3K inhibitor, in adults with advanced solid tumors. The study will evaluate the safety and tolerability of MTX-531, determine the maximum tolerated dose and recommended Phase 2 dose, and assess how the drug is processed by the body and its preliminary anti-tumor activity.

Read the detailed description

This first-in-human, Phase 1, open-label study will evaluate MTX-531, an investigational small-molecule inhibitor of EGFR and PI3K, as monotherapy in adults with advanced solid tumors.

The study will evaluate the safety and tolerability of MTX-531 and determine the maximum tolerated dose (MTD) and provisional recommended Phase 2 dose (RP2D). The study will also characterize the pharmacokinetic (PK) profile of MTX-531 and evaluate its preliminary clinical activity.

Safety assessments will include adverse events, dose-limiting toxicities, laboratory assessments, vital signs, and electrocardiograms. Pharmacokinetic assessments will evaluate plasma concentrations and other PK parameters of MTX-531. Anti-tumor activity will be assessed through radiographic tumor evaluations and investigator-assessed response according to RECIST version 1.1.

This study represents the first clinical study of MTX-531.

03

Conditions studied

  • Solid Tumors (Phase 1)
  • HNSCC
  • Endometrial Cancer
  • Her2-negative Metastatic Breast Cancer
  • Pan-RAS and BRAF Wild-type Advanced
  • Metastatic Colorectal Cancer (CRC)
  • Head and Neck Squamous Cell Carcinoma

Keywords

  • Solid Tumors
  • HNSCC
  • Endometrial Cancer
  • Her2-negative metastatic breast cancer
  • Pan-RAS
  • BRAF wild-type advanced
  • Metastatic Colorectal Cancer (CRC)
  • First-in-human
  • Phase 1 Solid Tumor
  • Phase 1
  • MTX-531
  • head and neck squamous cell carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age

  1. Age ≥18 years at the time of signing the .

    Disease Characteristics

  2. Has one of the following types of advanced or solid tumor :

    EC - No specific requirement

    1. FIGO stage III or IV (unresectable, recurrent, or disease) at study entry
    2. Received 1, 2, or 3 prior systemic regimens in any setting that must include:

    i. Anti-PD(L)1 in any setting (unless ) ii. A platinum-containing chemotherapy in any setting c. /neoadjuvant chemotherapy with or without additional anti-cancer therapy will not count as a prior regimen in the absence of recurrence during or within 6 months of completion of the last dose of planned therapy.

    MBC - No specific requirement

    1. Advanced or metastatic disease at the time of entry
    2. negative according to American Society of Clinical Oncology/College of American Pathologists guidelines, defined as a HER2 IHC score of 0 or 1+, or an IHC score of 2+ accompanied by a negative fluorescence, chromogenic, or silver in situ hybridization test indicating the absence of HER2 gene amplification, or a HER2/CEP17 ratio of \<2.0 based on the most recent tumor and assessed locally.
    3. Refractory to or relapsed after at 2, 3, 4, or 5, prior systemic regimens for metastatic disease, including (unless contraindicated):

    i. At least 1 cytotoxic chemotherapy regimen (as single agent or combination) in any setting.

    ii. At least 1 anticancer hormonal treatment in any setting. iii. At least 1 cyclin-dependent kinase inhibitor 4/6 in any setting. iv. Other treatments (eg, antibody-drug conjugates, PI3K pathway inhibitors) are allowed as long as the number of is not exceeded.

    d. Participants with bone-only metastases are excluded unless antitumor activity can be assessed using elevated baseline clinical tumor markers (eg, CA15-3, CA 27-29, CEA), or ctDNA.

    HNSCC - No specific requirement

    a. Recurrent, locally advanced or metastatic at time of entry b. Received 1, 2, 3, or 4 prior systemic regimens in any setting that must include: i. A platinum-based regimen in the relapse/metastatic setting ii. An anti-PD(L)1 in any setting.

    Advanced or metastatic CRC Pan-RAS and BRAF wildtype in tumor and/or ctDNA

    1. Advanced or metastatic disease at the time of entry
    2. Received 1, 2, 3, or 4 prior systemic regimens for the treatment of advanced or metastatic CRC that must include the following (unless contraindicated):

    i. Fluoropyrimidine ii. Irinotecan iii. Oxaliplatin iv. Biologic therapy (including but not limited to approved anti-VEGF, anti VEGFR or anti-EGFR monoclonal antibodies) v. Targeted therapy or immunotherapy if appropriate c. Adjuvant/neoadjuvant chemotherapy with or without additional anti-cancer therapy will not count as a prior regimen in the absence of recurrence during or within 6 months of completion of the last dose of planned therapy.

    Other solid tumors

    PIK3CA in tumor and/or ctDNA

    1. Other solid tumors, excluding primary CNS tumor
    2. At least 1 prior line of systemic anti-cancer therapy and no other standard therapeutic options.
    3. Tumor mutation status using a validated method such as FoundationOne®CDx must be known before enrollment. Locally available testing may also be acceptable upon discussion with the Medical Monitor.
  3. Has the ability to swallow and has a functional gastrointestinal tract.
  4. performance status score of 0, 1, or 2.
  5. by 1.1. If no measurable disease by RECIST 1.1, discuss with Medical Monitor the availability of other suitable tumor markers for assessments for antitumor activity.
  6. Baseline oxygen saturation on room air ≥92%.
  7. >50% as per echocardiography or multi-gated acquisition scan.
  8. Baseline ≤470 msec using Fridericia's QT correction formula. Note: This criterion does not apply to participants with right or left bundle branch block or on pacemakers, but prior discussion with the Medical Monitor is required.

    Clinical Laboratory Values

  9. \<8.0%.
  10. Adequate organ function, defined as follows:

    • Bone Marrow

      • ≥100,000/mm3
      • ≥9.0 g/dL (can be transfused within 7 days but cannot be transfusion dependent)
      • WBC >3000/mm3
      • >1500/mm3
    • Liver Function

      • Total ≤1.5 ×
      • ≤2.5 × ULN; ALT ≤2.5 × ULN (AST, ALT ≤5 × ULN if liver metastases are present)
    • Coagulation

      • ≤1.5; aPTT ≤1.5 × ULN in the absence of anticoagulant therapy or within acceptable parameters per local standard of care on anticoagulant therapy.
    • Renal Function

      • ≥60 mL/min either measured or calculated using standard Cockcroft-Gault formula.
      • Albumin ≥3.0 g/dL

    Prior Therapy

  11. Recovered to ≤Grade 1 toxicity from previous therapies, excluding alopecia, peripheral neuropathy, lymphopenia or therapy-related hypothyroidism or other endocrine disorders that are well controlled.
  12. Demonstrated progressive disease or intolerance to the last regimen. Sex and /Barrier Requirements
  13. Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    1. Male Participants:

      Participants are eligible to participate if they agree to the following during the study intervention period and for at least 180 days after the last dose of study intervention:

      • Refrain from donating sperm

      PLUS, either:

      • Be abstinent from intercourse where pregnancy can occur (abstinent on a long term and persistent basis) and agree to remain abstinent

      OR

      • Must agree to use [contraception /barrier] as detailed below: Agree to use an external condom and with (CBP) partner use an additional highly effective contraceptive method with a failure rate of \<1% per year as described in Section 10.4 when having sexual intercourse with a partner able to give birth who is not currently pregnant.
    2. Female Participants:

      • A participant is eligible to participate if not pregnant or breastfeeding, and one of the following conditions applies:

        • Is not of CBP.

    OR

    • Is of CBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), with low user dependency, as described in Section 10.4, during the study intervention period and for at least 90 days after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The Investigator should evaluate the potential for contraceptive method failure (eg, noncompliance, recently initiated) in relationship to the first dose of study intervention.

      • A CBP participant must have a negative highly sensitive pregnancy test (urine or serum, as required by local regulations) during screening and before the first dose of study intervention Day 1 of Cycle 1; see Section 8.3.5.
      • Additional requirements for pregnancy testing during and after study intervention are located in Section 8.3.5.
      • The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity where pregnancy can occur to decrease the risk for inclusion of a participant with an early undetected pregnancy.

    Informed Consent

  14. Signed informed consent as described in Section 10.1.2, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

    Other Inclusion Criteria

  15. Has a new or recent tumor biopsy (collected at screening, if feasible) or archived specimen within 5 years prior to screening.

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  1. History (within 2 years before screening) of a that is histologically distinct from the cancers being studied with the exception of adequately treated basal cell or squamous cell skin cancers and/or ductal carcinoma in situ of the breast or other malignancies that have a very low potential for recurrence or for confounding study results.
  2. Symptomatic requiring or other interventions. Participants with previously diagnosed brain metastases are eligible if treatment has been completed and the participant has recovered from the acute effects of radiation therapy or surgery prior to study entry, have discontinued corticosteroid treatment for these for at least 2 weeks before the first dose of MTX-531, and are neurologically stable.
  3. Known .
  4. Concurrent congestive heart failure, prior history of class III/ IV cardiac disease (), myocardial infarction within the last 6 months, unstable arrhythmias, unstable angina or other poorly controlled cardiac conditions (eg, arrhythmias) that are considered significant by the Investigator.
  5. Poorly controlled diabetes mellitus (including prior measurements or compliance).
  6. Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection requiring IV antibiotics.
  7. Experienced prior Grade 3-4 toxicities or severe toxicities from PI3K or EGFR inhibitors.
  8. Any other medical condition (eg, pulmonary, psychiatric, neurological, significant dermatologic conditions that may confound the interpretation of on-treatment toxicities or life-threatening toxicities from prior PI3K- or EGFR-directed therapies, if applicable) that in the opinion of the Investigator would place the participant at unacceptably high risk for toxicity.

    Prior/Concomitant Therapy

  9. Received systemic or local anticancer therapy within 3 weeks before the first dose of MTX-531 or 5 half-lives of the drug (whichever is less).
  10. Received radiotherapy within 2 weeks before the first dose of MTX-531 and has not recovered from all radiation-related toxicities. A 1-week washout is allowed for palliative radiation (≤2 weeks of treatment course) to non-CNS tumors. Inability to swallow oral medications or impaired gastrointestinal absorption due to anomalies of the gastrointestinal tract, such as gastrectomy or active inflammatory bowel disease.(Administration of oral medications via feeding tubes is not allowed.)
  11. Any condition requiring chronic administration of >10 mg daily prednisone or equivalent or other immunomodulators.
  12. Unable or unwilling to discontinue prohibited concomitant medications or adhere to restrictions for use of concomitant medications as defined in the protocol (see Section 6.9.2).

    Other Exclusion Criteria

  13. Pregnant or nursing women
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (estimated)

Study arms

  • Experimental
    MTX-531 Monotherapy

    Participants receive MTX-531 as monotherapy in sequential dose levels to evaluate the safety and tolerability of MTX-531, determine the maximum tolerated dose and recommended Phase 2 dose, and assess pharmacokinetics and preliminary clinical activity.

    Drug: MTX-531

Interventions

  • DrugMTX-531

    MTX-531 is an investigational small-molecule dual EGFR/PI3K inhibitor administered as monotherapy in adults with advanced solid tumors. Dose levels will be evaluated during dose escalation to assess safety, tolerability, pharmacokinetics, and preliminary clinical activity.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability profile of MTX-531

    To characterize the safety and tolerability profile of MTX-531 and to determine the MTD in participants with select advanced solid tumors.

    Time frame: From the time of first dose of study drug administration up to 21 days.

  2. Provisional RP2D For Further Evaluation of MTX-531

    To determine the provisional RP2D for further evaluation of MTX-531

    Time frame: From the time of first dose of study drug administration to 30 days after the last dose

Secondary outcomes

  1. Evaluation of the Preliminary Clinical Activity of MTX-531

    To evaluate the preliminary clinical activity of MTX-531 as assessed by the Investigator

    Time frame: Up to 30 days after the last dose

  2. Assessment of MTX-531's PK Profile

    To assess the PK profile of MTX-531

    Time frame: Up to the end of the last study drug administration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2028, 26 months later.

Of 154 industry-sponsored phase 1 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 72. This study's planned 26 months is below that.

Counting every sponsor, half of 270 studies reached it within 49 months; a quarter within 33 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2026
First posted
Oct 15, 2026
StartEst.
Oct 20, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Sep 29, 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07874880
Lead sponsor
MEKanistic Therapeutics, Inc.
Collaborators
Translational Drug Development
Responsible party
Sponsor
First posted
Oct 15, 2026
Start date
Oct 20, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Sep 29, 2029 (estimated)
Last update
Oct 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion